Of interest, in renal cell carcinoma patients the high‐affinity genotypes (plus the FCGR2C‐57Q variant) were associated with significantly increased tumor shrinkage and overall survival in response to a non‐antibody immune therapeutic, high‐dose aldesleukin (HD‐IL2).261. Here, IL2 is linked to renal cell carcinoma.